Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR733 Cell Injection in Acute Myeloid Leukemia
NCT06234904Phase 1Recruiting
- Sponsor
- Imbioray
- Start
- Mar 2024
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBR733 in acute myeloid leukemia (AML), sponsored by Imbioray. Primary endpoints: Dose Limiting Toxicity and Adverse Events. Started Mar 2024; status: recruiting.
02
Drugs
IBR733
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06234904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234904.